Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib study evaluating the safety and pharmacokinetics of SZN 043 in participants with severe alcohol-associated hepatitis

Next Previous
Trial Profile

A Phase Ib study evaluating the safety and pharmacokinetics of SZN 043 in participants with severe alcohol-associated hepatitis

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SZN 043 (Primary)
  • Indications Alcoholic hepatitis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Surrozen

Most Recent Events

  • 09 May 2025 According to a Surrozen media release, Company discontinued development of SZN-043 for the treatment of severe alcohol-associated hepatitis in the first quarter of 2025 due to insufficient clinical benefit in the Phase 1b trial.
  • 24 Mar 2025 According to a Surrozen media release, the company will discontinue development of SZN-043 in severe alcohol associated hepatitis, since there was not a sufficient early signal of clinical benefit to invest further, viewing the challenges with an acutely sick target population and a lengthy clinical development path.
  • 06 Nov 2024 According to a Surrozen media release, the company successfully completed dosing and 30-day follow-up for cohort 1 in its Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis (sAH).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top